Class: Centrally Acting Skeletal Muscle Relaxant
Dosage Forms. Tablet: 5 mg, 10 mg; Capsule, Extended Release: 15 mg, 30 mg
Common FDA Label Indication, Dosing, and Titration.
1. Skeletal muscle spasm: 5 mg po tid; may titrate to 10 mg po tid, may treat up to 2-3 wk
1. Temporomandibular joint disorder, 10 mg po daily × 3 wk
MOA. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems.
Drug Characteristics: Cyclobenzaprine
Medication Safety Issues: Cyclobenzaprine
Drug Interactions: Cyclobenzaprine
Adverse Reactions: Cyclobenzaprine
Efficacy Monitoring Parameters. Reduction in pain and muscle spasms.
Toxicity Monitoring Parameters. Seek medical attention if symptoms of hepatic failure occur during therapy with this agent.
Key Patient Counseling Points. Patients should avoid activities requiring mental alertness or coordination until drug effects are known, as drug may cause dizziness or sedative effects.
Clinical Pearls. Cyclobenzaprine is used for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults and should be used for only short periods (up to 2-3 wk). Should be used with caution in patients with glaucoma, increased intraocular pressure, urinary retention, etc, as cyclobenzaprine has anticholinergic-like effects. Avoid use in elderly, may be more sensitive to effects.